

THERAVECTYS FURTHER STRENGTHENS THE INTELLECTUAL PROPERTY OF ITS LENTIVIRAL VECTOR TECHNOLOGY

THERAVECTYS further strengthens the intellectual property of its Lentiviral Vector technology

PARIS, December 3, 2014

THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapies, announces the grant of its European Patent “Lentiviral Vectors Containing an MHC Class I Promoter” only two years after its initial filing.

Paris, December 1, 2014 - [THERAVECTYS](#), a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapies, announces the grant of its European Patent “**Lentiviral Vectors Containing an MHC Class I Promoter**” only two years after its initial filing ([website](#)).

The patent describes and claims **lentiviral vectors using MHC class I gene promoters**, “methods of making the vectors and methods of using them, including medicinal uses”.

Within the lentiviral vectors, the role of the promoter is to control the in vivo expression of the vectorized antigens. MHC class I promoters are naturally **highly active in Antigen Presenting Cells** thus inducing a **broad, intense and long-lasting CD4⁺/CD8⁺ immune response** following the injection of THERAVECTYS vaccines. The resulting stimulation of the cellular immune response leads to the elimination of the targeted infected or carcinogenic cells as well as all cells transduced by the vector post-injection. **The use of this family of promoters contributes to further enhance the efficacy and safety of THERAVECTYS lentiviral vector platform.**

THERAVECTYS owns over [20 patent families](#), either developed in-house or exclusively licensed from the Pasteur Institute from which the company has secured exclusive worldwide rights for the use of lentiviral vectors in vaccination and immunotherapy applications.

THERAVECTYS has implemented a systematic approach to strengthen its intellectual property **by protecting:**

- Any new indication-specific vaccines and immunotherapeutic candidates (including those derived from the company's proprietary Chimeric Antigen Receptors technology);
- All improvements brought to the lentiviral vector platform and the bioproduction process.

"I am extremely pleased with the grant of this important European patent protecting our MHC Class I promoters. It confirms that THERAVECTYS is at the forefront of lentiviral vectors optimization including packaging, delivery, expression, and immune response" says **Dr. Cécile BAUCHE, CSO**. *"This achievement clearly demonstrates our ability to build one of the broadest and most valuable lentiviral vectors patent portfolios in the world"*.

"The protection and the defense of our innovation is at the heart of our overall strategy" says **Renaud Vaillant, CEO**. *"This important milestone not only demonstrates our ability to stay ahead of the game but more importantly creates a key competitive advantage which we intend to transform into long-term value for ourselves, our partners and our investors"*.

About THERAVECTYS

THERAVECTYS is privately-owned, **fully-integrated discovery & clinical development biotech company** originating from the [Pasteur Institute](#).

THERAVECTYS capitalizes over 15 years of fundamental research in the field of lentiviral vectors and has secured **worldwide exclusive rights to Pasteur Institute intellectual property**.

Based on its lentiviral vector technology platform, THERAVECTYS develops **therapeutic vaccines and immunotherapies to fight cancers and infectious diseases**, including a proprietary and

differentiated **CAR T-cell technology platform**.

The company is strongly supported by renowned **investors** and former **global biopharmaceutical executives** and is rapidly progressing in its R&D activities and **in-house GMP production capabilities**.

Alone and in collaboration with partners, THERAVECTYS is accelerating its clinical development programs and is planning to **initiate two additional phase I/II clinical trials in oncology in 2015**.

For more information:

+33 1 43 90 19 20 - press@theravectys.com



THERAVECTYS - Villejuif BioPark, 1 Mail du Professeur Georges Mathé 94800 VILLEJUIF, FRANCE

www.theravectys.com